AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
etrasimod 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| immunomodulators, both stimulant/suppressive and stimulant | 5747 | 1206123-37-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Etrasimod is a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1, 4, and 5 (S1P1,4,5). Etrasimod has minimal activity on S1P3 (25-fold lower than Cmax at the recommended dose) and no activity on S1P2. Etrasimod partially and reversibly blocks the capacity of lymphocytes to egress from lymphoid organs, reducing the number of lymphocytes in peripheral blood. The mechanism by which etrasimod exerts therapeutic effects in UC is unknown but may involve the reduction of lymphocyte migration into the intestines.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 2 | mg | O |
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EGFR,EIF2AK3,ERBB2,GRK2,IKBKB,ITK,MAP2K6,MAPK7,MAPKAPK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PRKDC,TEK,TGFBR1 | 26 | |||
| kinase-selectivity-class | EIF2AK3,MAP2K6 | 2 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 10, 2023 | FDA | PFIZER INC |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Diabetic eye disease | 196.85 | 51.83 | 23 | 806 | 157 | 90627461 |
| Condition aggravated | 83.93 | 51.83 | 57 | 772 | 595488 | 90032130 |
| Drug ineffective | 55.70 | 51.83 | 65 | 764 | 1384233 | 89243385 |
| Type 2 diabetes mellitus | 52.98 | 51.83 | 29 | 800 | 203215 | 90424403 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Diabetic eye disease | 260.08 | 67.18 | 29 | 589 | 67 | 42620650 |
| Type 2 diabetes mellitus | 146.73 | 67.18 | 37 | 581 | 18434 | 42602283 |
| Drug ineffective | 84.81 | 67.18 | 70 | 548 | 630127 | 41990590 |
| Condition aggravated | 71.65 | 67.18 | 45 | 573 | 260709 | 42360008 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Diabetic eye disease | 466.02 | 51.74 | 52 | 1169 | 175 | 110587903 |
| Type 2 diabetes mellitus | 169.88 | 51.74 | 66 | 1155 | 177166 | 110410912 |
| Condition aggravated | 142.49 | 51.74 | 92 | 1129 | 734744 | 109853334 |
| Haematochezia | 96.25 | 51.74 | 39 | 1182 | 115485 | 110472593 |
| Colitis | 86.77 | 51.74 | 35 | 1186 | 102288 | 110485790 |
| Drug ineffective | 85.46 | 51.74 | 93 | 1128 | 1520447 | 109067631 |
| Colitis ulcerative | 85.20 | 51.74 | 32 | 1189 | 77331 | 110510747 |
| Rectal haemorrhage | 65.30 | 51.74 | 30 | 1191 | 119803 | 110468275 |
| Defaecation urgency | 55.85 | 51.74 | 14 | 1207 | 8733 | 110579345 |
| Faecal calprotectin increased | 54.30 | 51.74 | 13 | 1208 | 6706 | 110581372 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L04AE05 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Sphingosine-1-phosphate (S1P) receptor modulators |
| MeSH PA | D000091369 | Immunomodulating Agents |
| MeSH PA | D007155 | Immunologic Factors |
| CHEBI has role | CHEBI:33282 | antibacterial agent |
| CHEBI has role | CHEBI:35472 | anti-inflammatory drug |
| CHEBI has role | CHEBI:35705 | immunosuppressive agent |
| CHEBI has role | CHEBI:50177 | dermatologic drug |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
| CHEBI has role | CHEBI:144998 | sphingosine-1-phosphate receptor 1 antagonist |
Related Drugs by ATC class:
L04AE Sphingosine-1-phosphate (S1P) receptor modulators 4 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Moderately to severely active ulcerative colitis | indication | 64766004 | DOID:8577 |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Mobitz type II atrioventricular block | contraindication | 28189009 | DOID:11312 |
| Sick sinus syndrome | contraindication | 36083008 | DOID:13884 |
| Angina pectoris | contraindication | 194828000 | |
| Decompensated cardiac failure | contraindication | 195111005 | |
| Cerebrovascular accident | contraindication | 230690007 | |
| Transient ischemic attack | contraindication | 266257000 | DOID:224 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 2MG BASE | VELSIPITY | PFIZER | N216956 | Oct. 12, 2023 | RX | TABLET | ORAL | 9126932 | July 22, 2029 | A METHOD FOR TREATING ULCERATIVE COLITIS BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF ESTRASIMOD ARGININE |
| EQ 2MG BASE | VELSIPITY | PFIZER | N216956 | Oct. 12, 2023 | RX | TABLET | ORAL | 11007175 | Jan. 6, 2036 | A METHOD FOR TREATING ULCERATIVE COLITIS BY ADMINISTERING ESTRASIMOD ARGININE IN AN AMOUNT EQUIVALENT TO ABOUT 2.0 MG OF ESTRASIMOD |
| EQ 2MG BASE | VELSIPITY | PFIZER | N216956 | Oct. 12, 2023 | RX | TABLET | ORAL | 12156866 | Jan. 6, 2036 | A METHOD FOR TREATING ULCERATIVE COLITIS BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF ESTRASIMOD ARGININE AS CLAIMED |
| EQ 2MG BASE | VELSIPITY | PFIZER | N216956 | Oct. 12, 2023 | RX | TABLET | ORAL | 12377071 | Jan. 6, 2036 | A METHOD FOR TREATING ULCERATIVE COLITIS BY ADMINISTERING ESTRASIMOD L-ARGININE IN AN AMOUNT EQUIVALENT TO ABOUT 2.0 MG OF ESTRASIMOD |
| EQ 2MG BASE | VELSIPITY | PFIZER | N216956 | Oct. 12, 2023 | RX | TABLET | ORAL | 10676435 | June 21, 2036 | A METHOD FOR TREATING ULCERATIVE COLITIS BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF THE FORM OF ESTRASIMOD ARGININE AS CLAIMED |
| EQ 2MG BASE | VELSIPITY | PFIZER | N216956 | Oct. 12, 2023 | RX | TABLET | ORAL | 11884626 | June 21, 2036 | A METHOD FOR TREATING ULCERATIVE COLITIS BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF THE FORM OF ESTRASIMOD ARGININE AS CLAIMED |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 2MG BASE | VELSIPITY | PFIZER | N216956 | Oct. 12, 2023 | RX | TABLET | ORAL | Oct. 12, 2028 | NEW CHEMICAL ENTITY |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sphingosine 1-phosphate receptor 4 | GPCR | AGONIST | EC50 | 6.85 | DRUG LABEL | ||||
| Sphingosine 1-phosphate receptor 3 | GPCR | PARTIAL AGONIST | EC50 | 5.22 | DRUG LABEL | ||||
| Adenosine receptor A3 | GPCR | IC50 | 5.48 | CHEMBL | |||||
| Sphingosine 1-phosphate receptor 1 | GPCR | AGONIST | EC50 | 7.36 | DRUG LABEL | ||||
| Sphingosine 1-phosphate receptor 5 | GPCR | AGONIST | EC50 | 7.20 | DRUG LABEL |
External reference:
| ID | Source |
|---|---|
| CHEBI:229230 | CHEBI |
| CHEMBL3358920 | ChEMBL_ID |
| C000656249 | MESH_SUPPLEMENTAL_RECORD_UI |
| 9331 | IUPHAR_LIGAND_ID |
| DB14766 | DRUGBANK_ID |
| 4042709 | VANDF |
| C5139928 | UMLSCUI |
| CHEMBL3989933 | ChEMBL_ID |
| 10435 | INN_ID |
| 1206123-97-8 | SECONDARY_CAS_RN |
| 44623998 | PUBCHEM_CID |
| 372266 | MMSL |
| 42073 | MMSL |
| d10119 | MMSL |
| 019580 | NDDF |
| 019581 | NDDF |
| 6WH8495MMH | UNII |
| 2668045 | RXNORM |
| D10930 | KEGG_DRUG |
| 6WH8495MMH | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Velsipity | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0069-0274 | TABLET, FILM COATED | 2 mg | ORAL | NDA | 29 sections |